ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1541

Rank in Stocks #19257
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Share Price
$0.38249943
Market Cap
$160.28M
Change (1 day)
0.67%
Change (1 year)
-71.44%
Country
CN
Trade ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)

Category

Healthcare
Stock split history for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. stock (symbol: 1541) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 21, 2026.
One 1541 share bought prior to Oct 21, 2026 would equal to 0 1541 shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL